Celleron Therapeutics Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 7

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Celleron Therapeutics General Information

Description

Operator of a biotechnology platform intended to provide clinical development of new therapies to treat cancer. The company's platform provides personalized medicines that are developed using a portfolio of technologies to develop a new class of mechanism-based cancer drugs, which will improve the success rates of treatment, enabling patients to effectively prevent cancer cell growth.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Magdalen Centre, Oxford Science Park
  • Robert Robinson Avenue
  • Oxford OX4 4GA
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
IngenOx
Vertical(s)
Corporate Office
  • Magdalen Centre, Oxford Science Park
  • Robert Robinson Avenue
  • Oxford OX4 4GA
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Celleron Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 05-Jan-2023 Completed Out of Business
2. Later Stage VC 31-Jan-2017 Completed Pre-Clinical Trials
1. University Spin-Out 24-Jun-2004 Completed Startup
To view Celleron Therapeutics’s complete valuation and funding history, request access »

Celleron Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred Shares
Preferred Shares
Preferred Shares
Ordinary 27,833 $0.001234 $3.7 $3.7 1x $3.7 1.48%
Ordinary 176,471 $0.001234 $0.52 $0.52 1x $0.52 9.36%
To view Celleron Therapeutics’s complete cap table history, request access »

Celleron Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology platform intended to provide clinical development of new therapies to treat cancer. The comp
Drug Discovery
Oxford, United Kingdom
7 As of 2024

San Diego, CA
 

Abingdon, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Celleron Therapeutics Competitors (17)

One of Celleron Therapeutics’s 17 competitors is BPS Bioscience, a Corporation company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BPS Bioscience Corporation San Diego, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Sygnature Discovery Private Equity-Backed Nottingham, United Kingdom
Nuage Therapeutics Venture Capital-Backed Barcelona, Spain
Autolus Formerly VC-backed London, United Kingdom
You’re viewing 5 of 17 competitors. Get the full list »

Celleron Therapeutics Patents

Celleron Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4788332-A1 Combination of cxd101 and an il-15 superagonist to treat proliferative diseases such as cancer Pending 03-Oct-2023
WO-2025074090-A1 Combination of cxd101 and an il-15 superagonist to treat proliferative diseases such as cancer Inactive 03-Oct-2023
GB-202315149-D0 Combination therapy Inactive 03-Oct-2023
JP-2026536052-A Proliferative disorders, for example, the combination of cxd101 and il-15 superagonist to treat cancer. Pending 03-Oct-2023
EP-4313046-A1 Vaccine adjuvant Pending 31-Mar-2021 A61K31/454
To view Celleron Therapeutics’s complete patent history, request access »

Celleron Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Celleron Therapeutics Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
DAOL Investment PE/Buyout Minority
IMM Investment Asset Manager Minority
Korea Investment Partners Venture Capital Minority
NHN Investment Venture Capital Minority
Oxford Spin-out Equity Management Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Celleron Therapeutics FAQs

  • When was Celleron Therapeutics founded?

    Celleron Therapeutics was founded in 2004.

  • Where is Celleron Therapeutics headquartered?

    Celleron Therapeutics is headquartered in Oxford, United Kingdom.

  • What is the size of Celleron Therapeutics?

    Celleron Therapeutics has 7 total employees.

  • What industry is Celleron Therapeutics in?

    Celleron Therapeutics’s primary industry is Drug Discovery.

  • Is Celleron Therapeutics a private or public company?

    Celleron Therapeutics is a Private company.

  • What is Celleron Therapeutics’s current revenue?

    The current revenue for Celleron Therapeutics is .

  • How much funding has Celleron Therapeutics raised over time?

    Celleron Therapeutics has raised $15.9M.

  • Who are Celleron Therapeutics’s investors?

    DAOL Investment, IMM Investment, Korea Investment Partners, NHN Investment, and Oxford Spin-out Equity Management are 5 of 7 investors who have invested in Celleron Therapeutics.

  • Who are Celleron Therapeutics’s competitors?

    BPS Bioscience, Adaptimmune Therapeutics, Sygnature Discovery, Nuage Therapeutics, and Autolus are some of the 17 competitors of Celleron Therapeutics.

  • When was Celleron Therapeutics acquired?

    Celleron Therapeutics was acquired on 05-Jan-2023.

  • Who acquired Celleron Therapeutics?

    Celleron Therapeutics was acquired by IngenOx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process